Last edition
News about "Commercial Supply Partnership"
Quotient Sciences Expands Commercial Supply Partnership with Ipsen for Ultra-Rare FOP Therapy
Quotient Sciences has announced an extension of its commercial supply partnership with Ipsen to manufacture a treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder affecting fewer than 1,000 people worldwide.
Commercial Supply Partnership | 01/03/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members